Increasing Prevalence of Addison′s Disease in Germany: Health Insurance Data 2007-2011

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 50-71-HPA Axis
Clinical
Sunday, June 16, 2013: 1:45 PM-3:45 PM
Expo Halls ABC (Moscone Center)

Poster Board SUN-59
Gesine Meyer*1, Kathrin Neumann2, Roland Linder2 and Klaus Badenhoop1
1University Hospital Frankfurt, Frankfurt, Germany, 2Scientific Institute of the TK for Benefit and Efficiency in Health Care, Hamburg, Germany
There are no epidemiological data of Addison´s disease in Germany. Since there is no national registry for this rare disease alternative data sources need to be retrieved. The Technikerkrankenkasse (TK) is one of the large German health care insurance providers covering nearly 10% of the population. Documentation of diagnoses by all members with a doctor contact is evaluated by a scientific institute (Wissenschaftliches Institut der TK für Nutzen und Effizienz im Gesundheitswesen-WINEG, Hamburg).

Screening of the database for Addison´s disease was designed to filter out all causes of secondary, iatrogenic, traumatic or other non-idiopathic forms of primary adrenal failure.

The prevalence of Addison´s disease was found to range between 100 and 129 per million and showed a steady increase over the five years 2007-2011 of 22.5 %. The prevalence was lower in men (73-90 per million with an increase of 18.9 %) than in women (129-169 per million with an increase of 23.7 %). Prevalence data for the more frequent autoimmune diseases type 1 diabetes mellitus and vitiligo did not change significantly over the years 2008-2011. Autoimmune comorbidities were found in 58.4 % of Addison´s disease patients.

These data provide a first epidemiological profile of this rare and perilous endocrine disease in Germany. Although the prevalence of Addison´s disease appears slightly lower than in the Scandinavian countries, the increasing figures particularly in females over the last five years warrant further investigation into causes and triggers of autoimmune adrenal destruction. Despite the increasing prevalence Addison´s disease remains a rare disorder but may rise in the next decade requiring heightened awareness. Hereby we can show that health insurance data provide a valuable tool for epidemiological studies in the absence of national registries and allow providers to improve resource allocation and management of rare and also more common chronic diseases.

Nothing to Disclose: GM, KN, RL, KB

*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm